Advertisement


Drugs Controller General Of India Dgci
India  /  Published 26.01.23

India gets its own nasal vaccine

The nasal vaccine -- BBV154 -- had received Drugs Controller General of India's approval in November for restricted emergency use among adults...
By Our Web Desk in New Delhi

India  /  Published 16.12.22

Drug firm in cough syrup row wants to reopen

I have not done anything wrong, says Maiden Managing Director Naresh Kumar Goyal...
By Krishna N. Das in New Delhi

India  /  Published 16.12.22

India contests Africa child death charge

DGCI accuses WHO of relying on a 'premature deduction'...
By G.S. Mudur in New Delhi

India  /  Published 15.10.22

Cough syrups: 'Information inadequate so far'

The committee will recommend further course of action to the Drugs Controller General of India after examining and analysing the adverse event reports...
By PTI in New Delhi

India  /  Published 12.10.22

Syrup: Centre on WHO report

Development comes on a day the Haryana government ordered the halting of drug manufacturing at the Sonipat unit of Maiden Pharmaceuticals...
By PTI

Advertisement

India  /  Published 06.10.22

'Syrup samples sent for testing'

India's drug regulator Drugs Controller General of India has already initiated a probe and sought further details from the World Health Organisation...
By PTI in New Delhi

India  /  Published 29.09.22

DGCI okays export of malaria vaccine

Currently, only one vaccine against malaria is available globally and GSK is the manufacturer of that...
By PTI in New Delhi

India  /  Published 06.09.22

Intranasal Covid jab cleared

The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so far...
By Our Web Desk in New Delhi

India  /  Published 26.04.22

Covaxin nod for kids aged 6-12

The Drugs Controller General of India also gave restricted emergency use authorisation to Corbevax for those aged 5 to 12 years...
By Our Bureau, Agencies in New Delhi

India  /  Published 22.04.22

Plan to clear jab for 5-11 kids

The Subject Expert Committee has sought more data from Bharat Biotech to review its EUA application for the use of Covaxin in the 2-to-11 age group...
By PTI in New Delhi


Advertisement

Download our latest App

to get update on the go...

Advertisement

Advertisement
 
Copyright © 2020 The Telegraph. All rights reserved.